Related Experiment Videos
Thalidomide in type-2 lepra reaction--a clinical experience
V H Jadhav1, A H Patki, J M Mehta
1Dr. Bandorawala Leprosy Hospital, Pune.
Indian Journal of Leprosy
|July 1, 1990
Summary
Thalidomide effectively treats severe type-2 lepra reactions (ENL) in leprosy patients. Few side effects were noted, making it a safe option despite historical concerns.
Area of Science:
- Dermatology
- Infectious Diseases
- Pharmacology
Background:
- Leprosy reactions, particularly type-2 (erythema nodosum leprosum or ENL), pose significant clinical challenges.
- Managing ENL often requires effective and safe therapeutic interventions.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of thalidomide in treating type-2 leprosy reactions (ENL).
Main Methods:
- A clinical experience study involving 90 male patients with lepromatous leprosy (LL) or borderline lepromatous leprosy (BL).
- Patients received thalidomide for management of type-2 leprosy reactions.
Main Results:
- All 90 patients demonstrated a positive response to thalidomide treatment for ENL.
- Minor side effects included giddiness (10 patients) and gastrointestinal upset (7 patients).
- No major adverse events were reported during the study period.
Conclusions:
- Thalidomide is a highly effective treatment for severe type-2 leprosy reactions (ENL).
- The drug exhibits a favorable safety profile in this patient cohort, with manageable side effects.
- Thalidomide offers a valuable therapeutic option for ENL, distinct from its known embryopathic effects.